London (ots/PRNewswire) - Higher Levels of Social Assistance and Less Autonomy in This
Group of Patients
Results from a new French study reveal that nearly half of newly diagnosed patients with mild Alzheimer's disease also suffer from apathy and depression. The study also showed that this group of patients received significantly more social assistance, was less autonomous and had a lower daily activity functioning score.
"Our study highlights the size of the problem of apathy and depression in newly diagnosed patients and shows what a devastating impact this can have," says Philippe Robert, Centre Mmoire de Ressources et de Recherche (CMRR) de Nice [http://www.google.co.uk/u rl?sa=t&source=web&cd=1&ved=0CBoQFjAA&url=http%3A%2F%2Fwww.cmrr-nice. fr%2F&rct=j&q=CMRR%20NIce&ei=f70aTqzfKYaBhQeJssDMBQ&usg=AFQjCNFBWiuB2 zJU7jhiHBDXpkd_5QeSyQ&cad=rja ] . "We already know that these symptoms are the most frequent neuropsychiatric manifestations in Alzheimer's disease but this is the first time that the frequency has been observed using specific diagnostic criteria. We also know that people with apathy or depression and mild cognitive impairment have an increased risk of developing dementia, thus re-iterating the importance of intervention in helping delay the onset of Alzheimer's disease and the common neuropsychiatric conditions associated with it." He adds; "Early management and diagnosis of Alzheimer's disease using cognitive and neuropsychiatry signs might allow patients to remain independent for longer."
Apathy and depression are the most common neuropsychiatric features in Alzheimer's disease. The risk of conversion of Alzheimer's disease is significantly higher for patients with Mild Cognitive Impairment (MCI) who show a lack of interest, a core apathetic symptom.
The epidemiology study set out, using set diagnostic criteria, to estimate the frequency of depressive disorders and apathy in newly diagnosed Alzheimer's disease patients, and to describe the types of patients with these disorders. The cross-sectional, national French study involved 734 patients enrolled by 115 physicians.
The observed frequency of apathy and depression diagnosis was 41.6% and 47.9% respectively. Of the subjects involved, 32.4% of patients had both apathy and depression, 9.4% patients had apathy alone, 15.4% had depression alone and 42.9% neither had apathy nor depression.
The comparison study revealed that mild Alzheimer's disease patients with apathy received significantly more social assistance [Personalised Autonomy Allocation (APA)*] of 22.4% and 10.6% respectively (p<0.0001) than those without apathy. Similarly, mild Alzheimer's disease patients with depression received more social assistance than those without depression of 20.2% and 11.1% respectively (p<0.01).
The full results of the study will be presented at the Alzheimer's Association International Conference 2011 (AAIC 2011) in Paris, France.
Notes to Editors
*Personalised Autonomy Allocation (APA)
The APA is a French national solidarity allowance designed to allow persons over the age of 60, with stable and regular residence in France that have lost autonomy, to obtain any aid needed to accomplish everyday tasks, whether they are living at home or in an establishment
Eisai is one of the world's leading Research & Development-based pharmaceutical companies that has defined its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its Research & Development activities in three key areas:
- Neuroscience: Alzheimer's disease, multiple sclerosis,
neuropathic pain, epilepsy, depression
- Oncology: Anticancer therapies; tumour regression, tumour
suppression, antibodies, and Supportive cancer therapies; pain relief,
- Vascular/Immunological Reaction: Acute coronary syndrome,
atherothrombotic disease, sepsis, rheumatoid arthritis, psoriasis,
With operations in the U.S., Asia, Europe and its domestic home market of Japan, we employ more than 10,000 people worldwide, and reported consolidated sales of over GBP3.53 billion in FY2007, an increase of 8.9% year on year. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Hungary, Slovakia and the Netherlands.
For further information please visit our web site http://www.eisai.com
About Pfizer: Working Together for a Healthier World(TM)
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
1. Benoit M, Andrieu S, Lechowski L, Gillette-Guyonnet S, Robert PH, Vellas B; REAL-FR group. Apathy and depression in Alzheimer's disease are associated with functional deficit and psychotropic prescription. Int J Geriatr Psychiatry (2008) 23 (4):409 - 14
2. Robert PH, et al. Importance of lack of interest in patients with mild cognitive impairment. Am J Geriatri Psychiatry (2008); 16 (9): 770 - 776
3. Mulin E, et al. Diagnostic criteria for apathy in clinical practice. Int J Geriatr Psychiatry (2011); 26 (2) : 158 - 165
4. European Commission document on social security in France (2002) http://ec.europa.eu/employment_social/missoc/2002/socsot_franc e_en.pdf (last accessed July 2011)
For further information please contact: Benjamyn Tan / GurjitHothi,
Tonic Life Communications, +44(0)774-7111-217 /
+44(0)207-798-9998;Benjamyn.email@example.com / Aricept@toniclc.com;
Eisai Europe Ltd - CressidaRobson: +44(0)7908-314-155; Pfizer Press